Development and evaluation of various inhibitors and disinfectants for SARS-CoV-2
update：2022-06-28
Features
Using the infectious SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), we are evaluating and developing new therapeutic drug candidates as well as evaluating disinfectants. Further analyses such as mechanism of action and resistance may be applicable. Other pathogens, including influenza virus and drug-resistant bacteria, will be examined upon request and discussion. Through joint and collaborative research with domestic and overseas pharmaceutical companies and related companies, we have experience of their clinical application including basic research.Targeted Application(s)/Industry
We support development and evaluation of various inhibitors and disinfectants for variants of SARS-CoV-2 as well as wild type.Researchers
International Research Institute of Disaster Science
KODAMA Eiichi
, Professor
MD, PhD
Keywords
Related Information
・ Biyania et al. Development of robust isothermal RNA amplification assay for lab-free testing of RNA viruses. Scientific Reports 11, Article number: 15997, 2021
・ Yamada et al. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. Communications Biology 4, Article number: 1288, 2021 doi:10.1038/s42003-021-02813-8
・ Morioka et al. Factors associated with prolonged psychological distress among nurses and physicians engaged in COVID-19 patient care in hospitals in Singapore and Japan. Frontiers in Psychiatry 13:781796, 2022 doi:10.3389/fpsyt.2022.781796
・ Iwamoto et al. Change in use of pediatric oral antibiotics in Japan: Pre and post AMR action plan. Pediatrics International 2022 doi:10.1111/ped.15197 in printing
・ Suzuki et al. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict disease progression. European Journal of Clinical Investigation 2022 doi:10.1111/eci.13808 in printing
Prev
List
Next